Blog
RSS FeedPosted by Michael Wonder on 20 Jan 2022
Two anti-viral COVID-19 treatments approved
20 January 2022 - The Australian Government welcomes the Therapeutic Goods Administration’s provisional approval of the first oral treatments for COVID-19 ...
Posted by Michael Wonder on 20 Jan 2022
TGA provisionally approves Novavax (Biocelect) COVID-19 vaccine Nuvaxovid
20 January 2022 - The Therapeutic Goods Administration has granted provisional approval to Biocelect (on behalf of Novavax) for its ...
Posted by Michael Wonder on 19 Jan 2022
TGA provisionally approves two oral COVID-19 treatments, molnupiravir (Lagevrio) and nirmatrelvir and ritonavir (Paxlovid)
20 January 2022 - The TGA has granted provisional approval to two oral COVID-19 treatments: Paxlovid (nirmatrelvir and ritonavir, Pfizer) ...
Posted by Michael Wonder on 19 Jan 2022
Lieutenant General John Frewen says he expects TGA approval of Novavax vaccine is 'imminent'
19 January 2022 - The head of Australia's vaccine rollout expects one to two per cent of Australians who remain unvaccinated ...
Posted by Michael Wonder on 18 Jan 2022
TGA ‘knowingly putting pharmacists in serious danger’
18 January 2022 - The pharmacists’ union has accused the medical regulator of putting workers and customers at risk of ...
Posted by Michael Wonder on 18 Jan 2022
TGA in review (2021)
19 January 2022 - Using a liberal definition of what constitutes a 'new medicine', we have determined the TGA approved ...
Posted by Michael Wonder on 17 Jan 2022
TGA approves ‘game changing’ ovarian cancer drug bringing new hope to patients
18 January 2022 - Federal health authorities have approved a breakthrough drug for ovarian cancer, bringing a game-changing treatment option ...
Posted by Michael Wonder on 17 Jan 2022
TGA recognises the Gamaleya Institute vaccine (Sputnik V, Russian Federation) for international travel to Australia
17 January 2022 - Today, the TGA determined that an additional COVID-19 vaccine, the two dose course of the Gamaleya ...
Posted by Michael Wonder on 17 Jan 2022
ATAGI update following weekly COVID-19 meeting (12 January 2022)
17 January 2022 - Previously, severely immunocompromised people aged 12 years and older were recommended to receive a third primary dose ...
Posted by Michael Wonder on 16 Jan 2022
COVID-19 vaccine weekly safety report (13 January 2022)
13 January 2022 - To 9 January 2022, the TGA has received 952 reports which have been assessed as likely to ...
Posted by Michael Wonder on 16 Jan 2022
COVID-19 vaccine weekly safety report (6 January 2022)
17 January 2022 - To 2 January 2022, the TGA has received 415 reports which have been assessed as likely to ...
Posted by Michael Wonder on 04 Jan 2022
TGA grants provisional determination to AstraZeneca for COVID-19 prophylaxis and treatment, tixagevimab and cilgavimab (Evusheld)
4 January 2022 - On 4 January 2022, the TGA granted a further provisional determination to AstraZeneca in relation to ...
Posted by Michael Wonder on 28 Dec 2021
COVID-19 vaccine weekly safety report (23 December 2021)
23 December 2021 - To 19 December 2021, the TGA has received 415 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 Dec 2021
ATAGI update following weekly COVID-19 meeting (15 December 2021)
18 December 2021 - On Wednesday 15 December 2021 ATAGI reviewed the latest developments relating to COVID-19 and COVID-19 vaccine safety. ...
Posted by Michael Wonder on 16 Dec 2021
COVID-19 vaccine weekly safety report (16 December 2021)
16 December 2021 - To 12 December 2021, the TGA has received approximately 290 reports of suspected adverse events identified as ...